Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.

Author: CannP A, GiafferM H, HoldsworthC D, MansfieldJ C, McKennaD, ThorntonP C

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Balsalazide was effective as the sole treatment for patients with mild to moderately active ulcerative colitis, with significantly fewer withdrawals due to side-effects than in a similar group of patients taking sulfasalazine.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Sulfasalazine is accepted therapy for active ulcerative colitis, but side-effects and intolerance are common. Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule. AIM: To compare the safety and efficacy of su...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.2002.01151.x

データ提供：米国国立医学図書館（NLM）

Balsalazide: A Smoother Ride for Ulcerative Colitis

Ulcerative colitis, a chronic inflammatory bowel disease, can be a tough journey for patients. This study compares two medications, balsalazide and sulfasalazine, for the initial treatment of mild to moderate ulcerative colitis. Both drugs release 5-aminosalicylic acid in the colon, but balsalazide uses an inert carrier molecule, potentially leading to fewer side effects. The study found that while both drugs were effective, patients taking balsalazide experienced significantly fewer withdrawals due to side effects.

Balsalazide: Navigating the Colitis Desert

The study found that balsalazide, compared to sulfasalazine, was associated with a significantly lower rate of withdrawals due to adverse events. This finding suggests that balsalazide may provide a gentler path for patients navigating the challenges of ulcerative colitis, potentially minimizing the discomfort of side effects.

A Smoother Ride for Ulcerative Colitis

For patients with mild to moderate ulcerative colitis, this research offers a glimmer of hope. Balsalazide, with its reduced side effects, may provide a more comfortable and effective journey toward managing this challenging condition. This research, like finding a refreshing oasis in a parched desert, provides valuable insight for patients seeking a gentler approach to their treatment.

Dr.Camel's Conclusion

The journey through ulcerative colitis can be challenging, but this study offers a potential shortcut. Balsalazide emerges as a promising option, potentially providing a smoother and more tolerable path for patients. Like a camel caravan finding a reliable water source, this research helps us navigate the terrain of ulcerative colitis with greater ease and confidence.

Date :
  1. Date Completed 2002-03-19
  2. Date Revised 2019-09-01
Further Info :

Pubmed ID

11856080

DOI: Digital Object Identifier

10.1046/j.1365-2036.2002.01151.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.